Accès gratuit
| Numéro |
Biologie Aujourd’hui
Volume 213, Numéro 1-2, 2019
|
|
|---|---|---|
| Page(s) | 59 - 64 | |
| DOI | https://doi.org/10.1051/jbio/2019021 | |
| Publié en ligne | 5 juillet 2019 | |
- Alder Biopharmaceuticals, Inc. (2017). A multicenter assessment of ALD403 in frequent episodic migraine. Available from https://clinicaltrials.gov/ct2/show/NCT02559895. [Google Scholar]
- Buettner, C., Nir, R.R., Bertisch, S.M., Bernstein, C., Schain, A., Mittleman, M.A., Burstein, R. (2015). Simvastatin and vitamin D for migraine prevention: A randomized, controlled trial. Ann Neurol, 78, 970-981. [CrossRef] [PubMed] [Google Scholar]
- Cady, R.K., Mathew, N., Diener, H.C., Hu, P., Haas, M., Novak, G.P., Study Group. (2009). Evaluation of carisbamate for the treatment of migraine in a randomized, double-blind trial. Headache, 49, 216-226. [CrossRef] [PubMed] [Google Scholar]
- Cao, Y., Zheng, O.J. (2014). Tonabersat for migraine prophylaxis: A systematic review. Pain Physician, 17, 1-8. [Google Scholar]
- Caproni, S., Corbelli, I., Pini, L.A., Cupini, M.L., Calabresi, P., Sarchielli, P. (2011). Migraine preventive drug-induced weight gain may be mediated by effects on hypothalamic peptides: The results of a pilot study. Cephalalgia, 31, 543-549. [CrossRef] [PubMed] [Google Scholar]
- Chabi, A., Zhang, Y., Jackson, S., Cady, R., Lines, C., Herring, W.J., Connor, K.M., Michelson, D. (2015). Randomized controlled trial of the orexin receptor antagonist filorexant for migraine prophylaxis. Cephalalgia, 35, 379-388. [CrossRef] [PubMed] [Google Scholar]
- Eli Lilly and Company. (2017). Evaluation of LY2951742 in the prevention of episodic migraine – the EVOLVE-1 study. Available from https://clinicaltrials.gov/ct2/show/NCT02614183. [Google Scholar]
- Goadsby, P.J., Reuter, U., Hallström, Y., Broessner, G., Bonner, J.H., Zhang, F., Sapra, S., Picard, H., Mikol, D.D., Lenz, R.A. (2017). A controlled trial of erenumab for episodic migraine. N Engl J Med, 377, 2123-2132. [Google Scholar]
- Hoffmann, J., Supronsinchai, W., Akerman, S., Andreou, A.P., Winrow, C.J., Renger, J., Hargreaves, R., Goadsby, P.J. (2015). Evidence for orexinergic mechanisms in migraine. Neurobiol Dis, 74, 137-143. [CrossRef] [PubMed] [Google Scholar]
- Karsan, N., Gonzales, E.B., Dussor, G. (2018). Targeted acid-sensing ion channel therapies for migraine. Neurotherapeutics, 15, 402-414. [Google Scholar]
- Kwok, Y.H., Swift, J.E., Gazerani, P., Rolan, P. (2016). A double-blind, randomized, placebo-controlled pilot trial to determine the efficacy and safety of ibudilast, a potential glial attenuator, in chronic migraine. J Pain Res, 9, 889-907. [Google Scholar]
- Lambru, G., Andreou, A.P., Guglielmetti, M., Martelletti, P. (2018). Emerging drugs for migraine treatment: An update. Expert Opin Emerg Drugs, PMID 30484333. [Google Scholar]
- Olesen, J., Diener, H.C., Husstedt, I.W., Goadsby, P.J., Hall, D., Meier, U., Pollentier, S., Lesko, L.M., BIBN 4096 BS Clinical Proof of Concept Study Group. (2004). Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. N Engl J Med, 350, 1104-1110. [Google Scholar]
- Pradhan, A.A., Bertels, Z., Akerman, S. (2018). Targeted nitric oxide synthase inhibitors for migraine. Neurotherapeutics, 15, 391-401. [Google Scholar]
- Schwedt, T.J., Vargas, B. (2015). Neurostimulation for treatment of migraine and cluster headache. Pain Med, 16, 1827-1834. [CrossRef] [PubMed] [Google Scholar]
- Teva Branded Pharmaceutical Products, R&D Inc. (2017). Efficacy and safety of 2 dose regimens of TEV-48125 versus placebo for the preventive treatment of episodic migraine. Available from https://clinicaltrials.gov/ct2/show/NCT02629861. [Google Scholar]
- Tzabazis, A., Kori, S., Mechanic, J., Miller, J., Pascual, C., Manering, N., Carson, D., Klukinov, M., Spierings, E., Jacobs, D., Cuellar, J., Frey, W.H., 2nd, Hanson, L., Angst, M., Yeomans, D.C. (2017). Oxytocin and migraine headache. Headache, 57(Suppl 2), 64-75. [CrossRef] [PubMed] [Google Scholar]
- Vila-Pueyo, M. (2018). Targeted 5-HT1F therapies for migraine. Neurotherapeutics, 15, 291-303. [Google Scholar]
- Zagami, A.S., Edvinsson, L., Goadsby, P.J. (2014). Pituitary adenylate cyclase activating polypeptide and migraine. Ann Clin Transl Neurol, 1, 1036-1040. [CrossRef] [PubMed] [Google Scholar]
Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.
Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.
Le chargement des statistiques peut être long.